Cécile Bauche
Company: Alaya.bio
Job title: Chief Scientific Officer
Seminars:
Fireside Chat: Unveiling the Challenges that Arise in Scaling-Up from Pre-Clinical to Early Clinical Development 2:45 pm
Understanding what models and data may be required to progress towards the clinic Hearing about challenges encountered in scaling up to plan for more streamlined processes in the future Discovering the bottlenecks that have been faced in scaling up manufacturing to plan for potential challenges aheadRead more
day: Conference Day Two
Panel Discussion: Addressing the Safety of Delivery in the In Vivo CAR-T Space 1:00 pm
Navigating the safety of delivery mechanisms to collaborate in ensuring vectors are as safe as possible Clarifying the latest FDA guidelines in the ex vivo CAR-T space to apply insights to the in vivo space Evaluating how this may impact in vivo pipelines using viral vectors to plan for the futureRead more
day: Conference Day Two
Examining the Use of Lentivirus Vectors as a Delivery Mechanism to Engineer Cells In Vivo 11:30 am
Showcasing platforms using viral vectors such as lentiviruses to reflect on how this technology can be used to deliver in vivo cell and gene therapies Reaffirming the safety of viral vectors to deliver cell engineering and gene editing treatmentsRead more
day: Conference Day Two
Panel Discussion: Improving Target Specificity by Reviewing Methods to Reduce Off-Site Effects & Innovations Needed to Increase Target Precision 11:00 am
Identifying challenges in target specificity to collaboratively review current techniques Assessing the advantages and disadvantages of each method to improve target specificity Planning for future improvements and driving new innovations to elevate target specificityRead more
day: Conference Day One
Industry Leader’s Fireside Chat: Supercharging In Vivo as the Frontier of Cell Therapy & Comparing to Ex Vivo 9:00 am
Accentuating the bottlenecks of ex vivo therapies, such as the need for costly manufacturing processes and limited access, to consider the need to move towards a new engineering technique Championing in vivo therapies by highlighting the solutions they could bring to the ex vivo cell therapy and gene editing field Reaffirming the shift of interest…Read more
day: Conference Day One